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Abstract
Background: The objective of this observational study was to assess the influence of patient, tumor, professional
and hospital related characteristics on hospital variation concerning guideline adherence in non-Hodgkin’s
lymphoma (NHL) care.
Methods: Validated, guideline-based quality indicators (QIs) were used as a tool to assess guideline adherence
for NHL care. Multilevel logistic regression analyses were used to calculate variation between hospitals and to
identify characteristics explaining this variation. Data for the QIs regarding diagnostics, therapy, follow-up and
organization of care, together with patient, tumor and professional related characteristics were retrospectively collected
from medical records; hospital characteristics were derived from questionnaires and publically available data.
Results: Data of 423 patients diagnosed with NHL between October 2010 and December 2011 were analyzed.
Guideline adherence, as measured with the QIs, varied considerably between the 19 hospitals: >20 % variation was
identified in all 20 QIs and high variation between the hospitals (>50 %) was seen in 12 QIs, most frequently in the
treatment and follow-up domain.
Hospital variation in NHL care was associated more than once with the characteristics age, extranodal involvement,
multidisciplinary consultation, tumor type, tumor aggressiveness, LDH level, therapy used, hospital region and
availability of a PET-scanner.
Conclusion: Fifteen characteristics identified at the patient level and at the hospital level could partly explain hospital
variation in guideline adherence for NHL care. Particularly age was an important determinant: elderly were less likely to
receive care as measured in the QIs. The identification of determinants can be used to improve the quality of NHL care,
for example, for standardizing multidisciplinary consultations in daily practice.
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Background
Non-Hodgkin’s lymphoma (NHL) is the most common
hematologic neoplasm worldwide, and affects over
300,000 people each year [1]. In the United States, NHL
is the sixth most common cancer with an estimated
number of almost 70,000 new cases in 2013 [2]. This
heterogeneous group of malignant proliferations of
lymphocytes consists of more than 40 disease entities.
Approximately 50 % of the cases comprises the types
diffuse large B-cell lymphoma (DLBCL) and follicular
lymphoma [3].
Treatment of NHL is highly dependent on the type
and stage of the tumor. Primary therapy options include
chemotherapy, radiation therapy, immunotherapy and
wait-and-see policy. More effective therapy options are
emerging, partly due to many randomized controlled tri-
als in this field. Despite these improvements, the five-
year relative survival rate is still rather low for DLBCL
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patients (55–60 %), and for patients diagnosed with fol-
licular lymphoma this is 74–86 % [4, 5].
The emerging diagnostic and therapy options require
evidence-based guidelines to assist professionals and pa-
tients in their decision-making process for NHL care. These
guidelines should be in line with the description of care of
the Institute of Medicine (IOM): care should be safe, effect-
ive, patient-centered, timely, efficient and equitable [6].
However, previous studies showed variation in care for
NHL patients based on discrepancies between daily practice
and recommendations in guidelines [7–9]. Actual guideline
adherence was assessed with quality indicators, defined as
‘measurable elements of practice performance for which
there is evidence or consensus that they can assess the
quality of the care provided’ [10]. The suboptimal ad-
herence to guidelines in NHL patient management can
be an indication of suboptimal quality of care and
therefore may require tailored interventions, since
quality of care does not improve by itself. In order to
develop tailored improvement strategies, it is important
to gain more insight into factors that influence guide-
line adherence in daily practice on patient and hospital
level. In previous studies, determinants of NHL care fo-
cused on patient and tumor characteristics, such as
age, tumor stage and co-morbidity score [7–9, 11, 12].
However, little is known about the possible influence of
hospital factors. In other healthcare settings, patients’ age
and diagnosis are often associated with guideline adher-
ence [13–15], however, hospital factors (e.g. hospital size)
seem important to consider as well [13, 16–19].
In the current study, we assessed hospital variation in
guideline adherence in NHL care and to what extent
these variations can be explained by differences on pa-
tient and hospital level. This report builds upon previous
work where quality indicators were developed and mea-
sured to provide insight into guideline adherence for
NHL care [9, 20]. Together with insight into variation in
guideline adherence and accompanying determinants,
tailored strategies to improve NHL care can be designed.
Methods
Study design and population
This observational study was performed using baseline
measurements of the PEARL study (improvement of
patients’ hospital care for non-Hodgkin’s lymphoma), a
cluster randomized controlled trial (cRCT) to test and
evaluate tailored strategies to improve hospital care for
patients with NHL (registered at ClinicalTrial.gov:
NCT01562509) [21].
The extent of hospital variation was assessed in 19
hospitals across three regions of the Netherlands (north,
east and south), including university, teaching and non-
teaching hospitals. Patients eligible for this study were
defined as patients diagnosed with a mature B-, T- or
NK-cell neoplasm between October 2010 and December
2011, and older than 18 years at diagnosis. Patients with
cutaneous lymphomas or leukemia-type neoplasms were
excluded. The Dutch cancer registry was used by the
Netherlands Comprehensive Cancer Organisation (IKNL)
to make a list of potentially eligible patients in the partici-
pating hospitals. For each hospital a random sample of
25–30 patients was selected for data collection.
Data collection
Quality indicators
Data were assessed using systematically developed and
validated quality indicators (QIs), based on (inter)-
national evidence-based guidelines [9]. This set of 20
QIs was developed by professionals involved in NHL
care and covers important processes and structures in
management of NHL care in the domains diagnosis and
staging, treatment and follow-up, and organization and
coordination of care. In short, the QIs reflect quality of
NHL care as described in guidelines. Trained registra-
tion employees, from the IKNL, collected data from
medical records for the QIs using predefined registration
forms. Room for improvement was defined if quality in-
dicator scores were less than 90 % [9, 22–24].
Patient, tumor, professional and hospital related
characteristics
The characteristics were selected because of their potential
association with guideline adherence and quality of NHL
care, based on prior research findings [9, 11, 12, 25].
Potentially relevant patient and tumor related charac-
teristics were age (continuous), gender (male/female), co-
morbidities (yes/no), performance status (good/bad, good
indicating a WHO score <2 or Karnofsky score ≥60), pa-
tients’ preferences (yes/no objections), previous malignan-
cies (yes/no), tumor aggressiveness (yes/no), extranodal
involvement (yes/no, this term is used if the disease is not
in the lymph nodes (extranodal) or has spread from lymph
nodes to extranodal sites), Ann Arbor disease stage (I/II
or III/IV), tumor type (yes/no DLBCL), International
Prognostic Index (IPI) score (low/intermediate/high),
lactate-dehydrogenase level (LDH, yes/no high level (>250
u/L)) and hemoglobin level (Hb, yes/no aberrant level
(<7.5/8.5 or >10/11, females/males)). Factors related to
professionals (dichotomous, yes/no) included multidiscip-
linary team consultation (MTC), discussion in pathology
panel, in-hospital referral and therapy used (watch-and-
wait was defined as ‘no therapy used’). Patient, tumor and
professional related factors were all collected from medical
records at patient level.
The hospital characteristics include type of hospital (yes/
no teaching hospital), region of hospital (north/east/south),
availability of an in-hospital pathology laboratory (yes/no)
and PET-scanner (yes/no) and availability of professionals
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specialized in hematology, including a specialized oncology
nurse (yes/no). Hospital characteristics were collected for
each hospital from publically available data as well as from
a short, digital questionnaire (multiple choice questions)
sent to the contact person (oncologist or hematologist) at
each hospital.
Statistical analysis
Quality indicator scores and hospital variation were cal-
culated to provide insight into guideline adherence in
NHL care, which gives an indication of the quality of
care as delivered to NHL patients. Patient, tumor, pro-
fessional and hospital related characteristics were de-
scribed by calculating frequencies and means. Univariate
analyses (X2-test and t-test) were performed to study
correlations between the QI scores (dependent variables)
and the selected characteristics (independent variables).
Single correlations were only tested for QIs and charac-
teristics if the link between the two factors is clinically
explicable (e.g. radiology related QIs were not tested for
pathology related characteristics, since these processes
are independently performed from each other).
Multivariate logistic regression was performed to study
correlations for those characteristics with P < 0.20 in
univariate analyses. Correlations between the independ-
ent variables were also tested. If a correlation (>0.8) was
detected, only one variable was included in the multi-
variate analyses.
Finally, multilevel logistic regression analysis was used
to determine to what extent the QI scores were influ-
enced by the characteristics [26]. Multivariate backwards
regression models, including random coefficients, were
constructed for each quality indicator. The reason for
using this analysis was the hierarchical nature of the
characteristics, as patients (level 1) were nested in hospi-
tals (level 2). We considered P < 0.05 as statistically sig-
nificant and calculated the explained variance (R2) per
multilevel model with the Glimmix procedure using SAS
software (SAS12.0 for Windows; SAS Institute, Cary,
North Carolina, USA). Odds ratios (OR) were used to
describe the association between the characteristics and
quality indicator. An OR >1 indicates a positive associ-
ation with the quality indicator (greater relative chance
of guideline adherence if the determinant is present).
Ethics
On behalf of the research ethics committee (CMO) of
the Radboud university medical center, we hereby let
you know that the current study has been carried out in
accordance with the applicable rules concerning the re-
view of research ethics committees and informed con-
sent (registration number 2011/560).
The IKNL has contracts with each Dutch Hospital
about the Cancer Registry that all patients are informed
about the registration and are registered unless the pa-
tient has objected to be registered. The Netherlands
Cancer Registry is obliged to work according to the law
about protection of privacy data and the law “Geneeskun-
dige BehandelOvereenkomst”. All procedures to privacy of
doctors and patients is fixed in regulations. An independent
Committee of Privacy reassures that the Netherlands
Cancer Registry works is compliant to these regulations.
Based on this, consent of the patients for this specific
study was not applicable; according to the Dutch law all
cancer patients are included in the Netherlands Cancer
Registry as maintained by the IKNL, unless the patient has
objected to be registered.
Results
Patient, tumor and professional related characteristics
Table 1 shows the patient, tumor and professional re-
lated characteristics included in this study, measured at
patient level. In total, data were collected for 423 pa-
tients diagnosed with NHL between 2010–2011 across
19 Dutch hospitals. The mean age of the patients was
66 years (range 22–94), 57 % was male and 61 % had at
least one co-morbidity. Tumor related characteristics
showed that 61 % had extranodal involvement, 60 % was
diagnosed with an aggressive tumor and Ann Arbor
stage III of IV was observed in 68 % of the patients. Pro-
fessional related factors as discussion in a pathology panel
and an MTC were performed in 33 and 41 % of the pa-
tients, respectively. Of the 423 patients in this study, 75 %
received therapy, either chemotherapy, radiotherapy or a
combination of these two, as initial treatment. Three fac-
tors were excluded from further analyses: performance
status and IPI score because of too many missing values
(respectively, 83 and 58 % missings) and patient prefer-
ences because of <10 % variation (only 6 % had objections
concerning diagnostics or therapy).
Hospital characteristics
Table 2 outlines the characteristics of the participating
hospitals, measured at hospital level. Of the 19 hospi-
tals, 47 % was situated in the Northern region and 53 %
comprised teaching hospitals. An in-hospital pathology
laboratory was present in 47 % of the hospitals and 42
% had the availability of an in-hospital PET-scanner.
Most hospitals (87 %) had a specialized pathologist,
whereas 78 % had a specialized oncologist or hematologist
and 47 % a specialized radiologist/nuclear physician. In
68 % of the hospitals a specialized oncology nurse was
available. Two factors were excluded from further ana-
lyses because of high correlation with at least one other
hospital characteristic: trial participation and hospital
size.
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Quality indicators
Guideline adherence in NHL care was measured with a
set of 20 QIs, presented in Table 3. Room for improve-
ment (<90 % adherence) was seen in 18 out of 20 QIs.
Regarding diagnosis and staging, the indicator with the
lowest score was performance of all staging techniques
(QI4, 48 %) and the indicator with the highest score was
diagnosis based on morphology and immune phenotype
(QI3, 96 %). Indicators for treatment and follow-up
showed a range of 62–82 %, including complete evalu-
ation after chemotherapy (QI11) as lowest score and
reporting dose reduction for chemotherapy RCHOP
(QI13) as highest score. In the domain of organization and
coordination, the lowest score was for complete pathology
reports (QI16, 14 %) and the highest score for integrated
reporting of pathology techniques (QI15, 89 %).
In all three domains, QI scores differed considerably
between the 19 participating hospitals; variation in
guideline adherence (>20 %) among the hospitals was
noted in all 20 QIs. The lowest hospital variation was seen
for QIs concerning diagnosis of NHL based on morphology
and immune phenotype (QI3) and assessment of LDH level
(QI6), respectively 26 % (range 74–100) and 30 % (range
70–100). High variation (>50 %) between the hospitals was
seen in 12 of the 20 QIs, most frequently (N = 5) in the
treatment and follow-up domain.
Determinants of guideline adherence in NHL care
Table 3 displays, per quality indicator, the determinants
that significantly influence hospital variation concerning
guideline adherence for NHL care. In multilevel modeling,
15 of the 22 characteristics were involved with variation in
guideline adherence: 13 at patient level and 2 at hospital
level. Several characteristics influenced hospital variation in
only 1 quality indicator, including gender, co-morbidities,
previous malignancies, referral to another specialist, pres-
ence of a pathology panel and PET-scanner.
Determinants associated with 2 to 5 quality indicators
were extranodal involvement, MTC, DLBCL tumor type,
tumor aggressiveness, LDH and Hb level, therapy used
and hospital region. Of these 8 determinants, only ther-
apy showed a clear direction of effect: patients receiving
therapy were more likely to receive care as described in
the guidelines, including Ann Arbor classification (QI2),
performing all staging techniques (QI4) and assessment of
IPI (QI5) and LDH level (QI6). The other determinants
were both negatively (OR < 1) and positively (OR > 1)
linked to guideline adherence. For example, patients
Table 1 Patient related characteristics
Characteristics Patients (NTOTAL = 423)
Patient factors N %
Male sex 242 57
Mean age, years (range) 423 66 (22–94)
Co-morbidities (≥1) 256 61
Objections (patient preferences)A 25 6
Good performance statusB 67 94
Tumor related factors
Previous malignancies 71 17
Extranodal involvement 258 61
High LDH levelC 171 44
Aberrant Hb levelD 173 42
Ann Arbor stage III/IV 268 68
Aggressive tumor 254 60
DLBCL tumor typeE 194 46
IPI score (intermediate-) highB 49 38
Professional related factors
In-hospital referral 270 64
Multidisciplinary team consultation 172 41
Discussed in pathology panel 137 33
Therapy usedF 319 75
Abbreviations: LDH lactate-dehydrogenase, Hb Hemoglobin, DLBCL diffuse large
B-cell lymphoma, IPI International Prognostic Index
AExcluded from further analyses due to <10 % variation
BExcluded from further analyses due to >50 % missings, based on
WHO and Karnofsky scores
CHigh LDH level is defined as >250 U/l
DAberrant Hb level is defined as <8.5 or >11 mmol/l for males
and<7.5 or >10 mmol/l for females
ENon-DLBCL tumor types include follicular lymphoma (18 %),
marginal zone B-cell lymphoma (11 %), mantle-cell lymphoma (5 %),
lympho(plasma)cytic lymphoma (10 %), and miscellaneous (9 %)
FThe watch-and-wait management was coded as ‘no therapy used’
Table 2 Hospital characteristics
Characteristics Hospitals (NTOTAL = 19)
N %
Hospital region
North 9 47
East 5 26
South 5 26
Teaching hospital 10 53
In-hospital pathology laboratory 9 47
In-hospital PET-scanner 8 42
Specialized oncologist or hematologist 14 78
Specialized radiologist/nuclear physician 9 47
Specialized pathologist 16 87
Specialized oncology nurse 13 68
Trial participationA 12 63
Hospital size (no. of beds)A
Small (<350) 8 42
Medium (350–650) 5 26
Large (>650) 6 32
AExcluded from further analyses due to high correlation with other
hospital characteristics
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Table 3 Indicator scores and determinants for guideline adherence concerning NHL care
Quality Indicator N Indicator score (%) Range in 19 hospitals(%) OR (95 % CI) P-value Explained variance (%)
Diagnosis and staging
QI1 Diagnosis based on histological examination or an
excision or wide incision biopsy
369 79 53–100 5
Older age 0.97 (0.95–0.99) <0.01
QI2 Patients staged according to Ann Arbor classification 390 81 59–100 35
Older age 0.93 (0.90–0.95) <0.01
Therapy used 7.55 (4.04–14.00) <0.01
QI3 Diagnosis based on morphology and immune
phenotype
376 96 74–100 n.a.
QI4 Staging techniques include CT-scans, bone marrow
aspirate, and bone biopsy
421 48 0–74 14
Older age 0.98 (0.96–0.99) 0.02
Extranodal involvement 0.52 (0.33–0.84) <0.01
Discussed in MTC 1.88 (1.10–3.20) 0.02
Aberrant Hb level 0.54 (0.34–0.86) 0.01
Therapy used 3.08 (1.76–5.39) <0.01
QI5 Assessment of International Prognostic Index for
patients with aggressive NHL
250 43 0–81 17
Older age 0.97 (0.95–0.99) 0.01
DLBCL tumor type 2.85 (1.07–4.82) 0.03
Therapy used 8.70 (1.82–41.50) <0.01
QI6 Assessment of LDH level 423 92 70–100 9
Discussed in MTC 0.42 (0.19–0.94) 0.03
Therapy used 2.92 (1.36–6.27) <0.01
QI7 Examination of blood counts 422 82 14–100 n.a.
Treatment and follow-up
QI8 Reporting of response to therapy using predefined
terminology
304 73 53–100 2
High LDH level 1.79 (1.03–3.11) 0.04
QI9 Lesions documented in radiology report before therapy 344 67 22–90 n.a.
QI10 Lesions documented in radiology report after therapy 114 58 0–100 24
DLBCL tumor type 0.34 (0.15–0.79) 0.01
Co-morbidities (≥1) 0.34 (0.15–0.81) 0.02
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Table 3 Indicator scores and determinants for guideline adherence concerning NHL care (Continued)
Hospital region 1 1.08 (0.38–3.07)
2 4.10 (1.48–11.40)
3 Ref. 0.02
QI11 Evaluation after chemotherapy with (PET)CT-scans,
bone marrow aspirate, and bone biopsy
246 62 29–100 30
Extranodal involvement 0.18 (0.09–0.34) <0.01
Hospital region 1 0.93 (0.47–1.84)
2 4.54 (1.88–10.96)
3 Ref. <0.01
QI12 Patients with DLBCL received RCHOP chemotherapy 194 78 44–100 26
Older age 0.92 (0.88–0.95) <0.01
QI13 Dose of RCHOP was not reduced or reason for
reduction was reported
111 82 40–100 8
Extranodal involvement 0.31 (0.10–0.99) 0.05
Quality Indicator N Indicator score (%) Range in 19 hospitals (%) OR (95 % CI) P-value Explained variance (%)
Organization and coordination of care
QI14 Sending of unfixed biopsy material 321 41 0–91 n.a.
QI15 Integrated reporting of pathology techniques 365 89 35–100 11
Extranodal involvement 2.46 (1.10–5.50) 0.03
Discussed in pathology panel 5.25 (1.75–15.74) <0.01
QI16 Pathology report describes all necessary, predefined
characteristics
378 14 0–47 23
Discussed in MTC 2.46 (1.10–5.51) 0.03
Hospital region 1 2.73 (0.62–12.04)
2 0.17 (0.02–1.31)
3 Ref. 0.04
QI17 Patients discussed in multidisciplinary consultations 422 41 4–96 9
Availability of PET-scanner 4.22 (1.01–17.56) 0.05
QI18 Results of bone marrow pathology known before
start of treatment
317 83 43–100 11
Aggressive tumor 0.30 (0.13–0.70) <0.01
Aberrant Hb level 0.38 (0.20–0.72) <0.01
QI19 Diagnostic period of 4 weeks after first visit to
the hospital
420 47 22–70 10
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Table 3 Indicator scores and determinants for guideline adherence concerning NHL care (Continued)
Previous malignancies 0.52 (0.29–0.95) 0.03
Extranodal involvement 1.72 (1.11–2.66) 0.02
In-hospital referral 0.52 (0.34–0.81) <0.01
High LDH level 1.9 2 (1.27–3.03) <0.01
QI20 Start of therapy within 2 weeks after diagnostic
period
313 58 37–79 9
Male gender 1.69 (1.03–2.76) 0.04
Aggressive tumor 1.99 (1.17–3.41) 0.01
High LDH level 1.92 (1.16–3.19) 0.01
Abbreviations: MTC, multidisciplinary team consultation; DLBCL, diffuse large B-cell lymphoma; LDH, lactate-dehydrogenase; Hb, Hemoglobin; RCHOP, ritixumab-involved chemotherapy
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discussed in an MTC were less likely to receive an LDH
level assessment (QI6), whereas they were more likely to
receive all staging techniques (QI4).
The main patient characteristic associated with guide-
line adherence was age (5 out of 20 quality indicators).
In particular, older people were less likely to receive care
as measured by the QIs, including correct diagnostic bi-
opsy performance (QI1), Ann Arbor staging (QI2), per-
forming all staging techniques (QI4), assessment of IPI
risk factor (QI5), and receiving R-CHOP chemotherapy
(QI12), compared to younger patients.
Hospital characteristics associated with QI scores in
this dataset included hospital region and an in-hospital
PET-scanner. Hospitals in region 2 showed more docu-
mentation of target lesions in radiology reports after
therapy (QI10) and more complete reports therapy eval-
uations (QI11), whereas they showed less complete re-
ports for pathology (QI16), compared to the other two
regions. The availability of an in-hospital PET-scanner
was positively associated with a multidisciplinary discus-
sion of patients (QI17). Participation in trials and hos-
pital size were not included in multivariate analysis,
because of the high correlation with hospital type, and
availability of an in-hospital pathology laboratory and
PET-scanner.
Table 3 also shows the explained variance of the deter-
minants included in the final multilevel model. A sub-
stantial part of the variation in guideline adherence can
be explained by patient and/or hospital characteristics:
ten QIs showed that determinants could explain the
variation for at least 10 %. Variation regarding Ann
Arbor staging (QI2), evaluation with CT-scans after
therapy (QI11) and R-CHOP chemotherapy for DLBCL
patients (QI12) showed relatively large explained vari-
ances of, respectively, 35, 30 and 26 %.
Discussion
This study demonstrated substantial hospital variation in
guideline adherence for NHL care. Fifteen characteristics
at the patient level could partly explain this variation,
such as extranodal involvement, multidisciplinary consult-
ation, tumor type, therapy used and hospital region. Hos-
pital characteristics contributed less to the variation in
adherence than patient, tumor and professional related
characteristics. Patients’ age was involved most frequently
as determinant, illustrating that older people are less likely
to receive NHL care as described in the guidelines.
Our study showed large gaps between daily practice
performance and care as described in the evidence-
based guidelines. Large variation in guideline adherence
between hospitals is often associated with lower quality
of care, since guidelines aim to assist professionals to de-
liver the most optimal care. However, less adherence
does not always indicate lower quality of care: complying
with patient preferences or performing less diagnostics
due to a low performance status can also point towards
patient-centered, safe and deliberately delivered care. It
is believed that variation due to deliberately deviate from
guidelines is reflected in the upper 10 % of QI scores
(90–100 %). Therefore, many studies indicate room for
improvement if guideline adherence, as measured by in-
dicators, is below 90 % [9, 22–24]. In our study, 18 out
of 20 QIs showed room for improvement, of which 12
QIs demonstrated high hospital variation (>50 %), indi-
cating other factors than patient preferences or perform-
ance status might play a role. Similar to our study,
Weeks et al. [27] found high variation in NHL manage-
ment decisions, for example in performing a PET-scan
(range 38–95 %) or a bone marrow biopsy (range 21–99
%). Studies concerning other tumor types also showed
variation in delivered care between hospitals [18, 28–31].
While this is the first study to investigate determinants
at patient as well as hospital level for guideline adher-
ence, and indirectly for the quality of care for NHL pa-
tients, other studies examining multilevel determinants
have been carried out in several areas, including lung,
prostate and (colo)rectal cancer [18, 29, 32–34]. Schroeck
et al. [33] provided insight into adherence to QIs for pros-
tate cancer and its regional variation. Most measures
showed low adherence rates and high regional variation,
for example 72 % variation in follow-up with radiation on-
cologists (range 14–86 %). They showed that characteris-
tics such as age, clinical stage and number of urologists
explained the differences for 5–20 %. Etzioni et al. [32]
showed that characteristics as higher-volume surgeons
and teaching hospitals contributed to long-term survival
in rectal cancer patients, whereas Sacerdote et al. [34]
found several social, clinical and hospital characteristics to
be associated with the treatment of colorectal cancer, for
example, age, gender, hospital volume and an in-hospital
radiotherapy service. Mathoulin et al. [29] investigated the
quality of colorectal cancer surgery and found several as-
sociations with patient, tumor and hospital related factors,
such as age, disease stage and hospital type. Finally,
Ouwens et al. [18] found patient characteristics to have a
greater influence on quality of integrated care than profes-
sional or hospital characteristics for patients with non-
small cell lung cancer.
Several determinants of guideline adherence and NHL
care were found in our study as well. Regarding patient
factors, especially patients’ age appeared to influence
variation in guideline adherence for NHL care most. For
older patients, it can be argued that suboptimal diagnos-
tics and suboptimal but better tolerated therapies some-
times are the best achievable care. However, the reasons
for deviation from the guideline should be well thought
out and documented by the professionals, which may be
influenced by available information for decision making,
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professionals’ choice or patient preferences. Unfortu-
nately, we were not able to include arguments to deliber-
ately deviate from guideline recommendations, since
these are frequently not documented (in a standardized
way) in medical records.
Previous studies found patients’ age as an important
factor for delivered NHL care: they studied elderly
DLBCL patients, defined as patients aged over 60 or
75 years [11, 12, 25]. Younger age and better perform-
ance status were associated with receiving CHOP-like
chemotherapy. Van de Schans et al. [12] showed age as
the only factor associated with receiving less than six cy-
cles of CHOP-like chemotherapy (adjusted for variables
as gender and co-morbidity). Concerning overall sur-
vival, all three studies concluded that optimal therapy
for elderly was associated with better outcomes, after
case-mix corrections [11, 12, 25]. After multivariate ana-
lyses, Trebouet et al. [35] found also a relation between
treatment administration and improved survival in pa-
tients over 90 years of age with aggressive NHL. An im-
portant drawback of intensive chemotherapy is treatment
related toxicity. The elderly are more susceptible to com-
plications, which makes it even more important to accur-
ately select patients for therapy [11]. They stated that
elderly are more susceptible to develop complications,
which makes it even more important to accurately select
patients for therapy. The judgment of professionals must
be underscored in this selection process. A possible option
to optimize outcomes was proposed by Lin et al. [25]; they
opted implementation of tailored interventions to improve
the performance status of patients before the start of ther-
apy. In addition, in other fields of oncology lower guide-
line adherence was seen for elderly as well [34, 36].
Suggested reasons for the lower rates were that elderly pa-
tients receive less diagnostics and/or therapy for medical
reasons, such as higher burden of co-morbidities [34], or
diagnosis of advanced disease stages [36], which was ini-
tially seen in our dataset as well (data not explicitly
shown). However, co-morbidities and disease stage were
included in our analyses and age remained a determinant
in the final models.
Besides age, several other tumor and patient related
determinants were involved in explaining hospital variation,
including previous malignancies, LDH and Hb level, gen-
der, co-morbidity, extranodal involvement, tumor type and
tumor aggressiveness. Most of these aspects are common
factors measured in NHL research concerning prognostic
factors and survival analyses [11, 12, 25, 35]. Unfortunately,
this literature shows involvement of the factors with sur-
vival in univariate analyses, but not in multivariate analyses.
Tumor type and aggressiveness are often not assessed, since
studies regularly select only DLBCL or aggressive tumors
as subjects of interest [11, 25, 37]. Kuper-Hommel et al.
[37, 38] investigated differences in therapy and outcome
between patients with nodal and extranodal lymphomas in
two large population-based studies. They showed that pa-
tients with extranodal lymphomas were less often optimally
treated but did not find clear differences in overall survival.
In our study, patients with extranodal involvement received
less often all required staging techniques and showed more
often dose reductions during R-CHOP chemotherapy or re-
ductions without reporting the reason.
Not all determinants found seem directly relevant for
clinical practice, such as the influence of the Hb level on
QI18: pathology results have to be known before the
start of treatment. A possible explanation could be that
the urge of starting therapy is higher for patients with a
aberrant Hb level and an aggressive tumor. It seems
valuable to explore these determinants in other NHL
populations.
Of the professional and hospital related determinants
for hospital variation in NHL care, treatment is an im-
portant factor in relation to better survival, as discussed
above. Factors as MTC, hospital region, in-hospital re-
ferral, PET-scanner and discussion in a pathology panel
are often not taken into account in survival analyses.
The possible relation of these factors with overall sur-
vival is an interesting issue to address in future research.
Hospital region will probably be one of the most chal-
lenging determinants, since hospitals cannot move to
another geographical region and regional collaborations
are embedded, which might be tough to effect change
upon. Nevertheless, guideline adherence and quality of
care described per region can give valuable insight into
regional differences concerning interpretation and rating
of the guideline recommendations and provide possible
points of interest for improving quality of care.
Strengths of this study are the large study sample (N =
423) derived from a population-based cancer registry
and the validated guideline-based QIs used for the as-
sessment of variation in guideline adherence for NHL
care. These factors contribute to the reliability of our re-
sults. Another factor contributing to a reliable dataset is
that trained registration employees of the IKNL collected
the data independently of the project team. An additional
strength of our study is that 2 levels of potential determi-
nants were included, namely patient and hospital level.
Multilevel analyses made it possible to include these fac-
tors in one regression model per quality indicator.
There are also some limitations that need to be ad-
dressed. First, characteristics at the level of professionals
were not taken into account, since NHL care is provided
by a multidisciplinary team of a hematologist and/or
(radiation)oncologist, radiologist, nuclear physician, path-
ologist and oncology nurse. It was not possible to relate
one professional to one patient, which is necessary for in-
clusion of characteristics at professional level. However,
some professional related factors measured at patients
Stienen et al. BMC Cancer  (2015) 15:578 Page 9 of 11
level were included in our study, such as patients dis-
cussed in MTC and therapy used. Second, only two of
eight hospital characteristics included for analyses were
found to have significant impact in the final multilevel
models. This can be caused by the limited sample size of
19 hospitals, indicating more hospitals may be needed for
possible future research. Third, no hospitals from the
Western part of the Netherlands were included in our
study, which might have introduced some selection bias.
However, we did include 19 of the 91 Dutch hospitals, in-
cluding three different regions, representing 21 % of the
Dutch hospital population. Last, a significant amount (>50
%) of data was missing for the parameters performance
status and IPI score. One of the reasons for this could be
that only official WHO scores and Karnofsky scores were
collected, excluding general terms as ‘healthy man’ or ‘vital
women’. Arguments for not calculating the IPI score in-
cluded that therapy choices do not change for most pa-
tients based on the IPI score, except for patients
participating in clinical trials.
Conclusion
In conclusion, this study showed considerable hospital
variation in guideline adherence, as an indication for
quality of delivered NHL care, including the domains
diagnosis and staging, treatment and follow-up and
organization and coordination of care. Our study dem-
onstrated that patient characteristics appear to have
more influence on guideline adherence than hospital
characteristics, especially patients’ age. Tailored strat-
egies to optimize NHL care should take into account the
determinants identified in this study. Especially for older
patients, reasons for not performing all necessary diag-
nostics and staging techniques should be a topic of
interest, taking into account safe and patient-centered
care as well.
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